Tags

Type your tag names separated by a space and hit enter

Future indications for macrolides.
Pediatr Infect Dis J. 1997 Apr; 16(4):457-62.PI

Abstract

The antimicrobial spectrum of azithromycin and clarithromycin suggests a number of further uses for these newer macrolides. Favorable clinical and bacteriologic responses have been reported with both antibiotics in children with community-acquired pneumonia. Response rates were high for overall patient populations and for subgroups with infection caused by Mycoplasma pneumoniae and Chlamydia pneumoniae. Treatment with azithromycin or clarithromycin has resulted in a reduction in mycobacteremia and an improvement in clinical symptoms in adult AIDS patients with disseminated Mycobacterium avium-intracellulare complex. Prophylactic treatment with azithromycin may prevent M. avium-intracellulare complex, especially when combined with rifabutin. Preliminary evidence suggests that both azithromycin and clarithromycin in multidrug combinations may effectively eradicate Helicobacter pylori and that azithromycin may be useful in treating bacterial gastritis caused by Campylobacter species. Trachoma and infections caused by Bordetella pertussis and Ureaplasma urealyticum are other possible future indications for the newer macrolides. Limited clinical evidence also suggests that azithromycin may be effective in the prevention and treatment of malaria.

Authors+Show Affiliations

Department of Pediatrics, Birmingham Heartlands Hospital, Bordesley Green East, UK.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9109159

Citation

Tarlow, M J., et al. "Future Indications for Macrolides." The Pediatric Infectious Disease Journal, vol. 16, no. 4, 1997, pp. 457-62.
Tarlow MJ, Block SL, Harris J, et al. Future indications for macrolides. Pediatr Infect Dis J. 1997;16(4):457-62.
Tarlow, M. J., Block, S. L., Harris, J., & Kolokathis, A. (1997). Future indications for macrolides. The Pediatric Infectious Disease Journal, 16(4), 457-62.
Tarlow MJ, et al. Future Indications for Macrolides. Pediatr Infect Dis J. 1997;16(4):457-62. PubMed PMID: 9109159.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Future indications for macrolides. AU - Tarlow,M J, AU - Block,S L, AU - Harris,J, AU - Kolokathis,A, PY - 1997/4/1/pubmed PY - 1997/4/1/medline PY - 1997/4/1/entrez SP - 457 EP - 62 JF - The Pediatric infectious disease journal JO - Pediatr Infect Dis J VL - 16 IS - 4 N2 - The antimicrobial spectrum of azithromycin and clarithromycin suggests a number of further uses for these newer macrolides. Favorable clinical and bacteriologic responses have been reported with both antibiotics in children with community-acquired pneumonia. Response rates were high for overall patient populations and for subgroups with infection caused by Mycoplasma pneumoniae and Chlamydia pneumoniae. Treatment with azithromycin or clarithromycin has resulted in a reduction in mycobacteremia and an improvement in clinical symptoms in adult AIDS patients with disseminated Mycobacterium avium-intracellulare complex. Prophylactic treatment with azithromycin may prevent M. avium-intracellulare complex, especially when combined with rifabutin. Preliminary evidence suggests that both azithromycin and clarithromycin in multidrug combinations may effectively eradicate Helicobacter pylori and that azithromycin may be useful in treating bacterial gastritis caused by Campylobacter species. Trachoma and infections caused by Bordetella pertussis and Ureaplasma urealyticum are other possible future indications for the newer macrolides. Limited clinical evidence also suggests that azithromycin may be effective in the prevention and treatment of malaria. SN - 0891-3668 UR - https://www.unboundmedicine.com/medline/citation/9109159/Future_indications_for_macrolides_ L2 - https://doi.org/10.1097/00006454-199704000-00030 DB - PRIME DP - Unbound Medicine ER -